Trials / Completed
CompletedNCT00097435
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
A Multi-Center, Randomized, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Albuferon (Recombinant Human Albumin-Interferon Alfa Fusion Protein) in Combination With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 115 (actual)
- Sponsor
- Human Genome Sciences Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to respond to previous interferon alfa therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Albuferon | |
| DRUG | Ribavirin |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2004-11-24
- Last updated
- 2013-08-02
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00097435. Inclusion in this directory is not an endorsement.